Superworth

Aurinia Pharmaceuticals AUPH

Drug Manufacturers - General, Healthcare
$16.14
−3.06%
Market cap
$2.2B
PE
n/m
not a meaningful number
Forward PE
n/m
not a meaningful number
Price to sales
6.7×
EV/EBIT
11.8×
Revenue, 12 months
$321.7M
+21% on a year ago
Net margin
97.7%
Free cash flow yield
n/m
not a meaningful number

Aurinia Pharmaceuticals trades at 6.7× sales. Revenue was $321.7M over the last twelve months, up 21% on a year earlier with a 98% net margin.

Charts

Financials

Income statement for AUPH, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$45.1M+59%$50.3M+46%$57.2M+38%$67.8M+24%$59.9M+33%$62.5M+24%$70M+22%$73.5M+8%$77.1M+29%$77.7M+24%$83.2M+19%$83.7M+14%
Cost of revenue$5.4M+296%$7.8M+1741%$8.9M+470%$6M−11%$5.6M+3%$8.6M+11%$7.1M−20%$8.2M+36%$8.8M+59%$6.5M−24%$6.6M−8%$8.3M+2%
Gross profit$39.7M+47%$42.6M+25%$48.3M+21%$61.7M+29%$54.3M+37%$53.9M+27%$62.9M+30%$65.3M+6%$68.3M+26%$71.2M+32%$76.7M+22%$75.4M+16%
R&D$10.2M+4%$5.6M−58%$4.1M−68%$3M−78%$8.1M−21%$5.7M+4%$7.4M+82%$8.4M+177%$10.9M+34%$7.5M+30%$13.1M+76%$16.6M+97%
SG&A$50.1M+6%$47.7M−5%$44.9M−5%$42.4M−11%$37M−26%$20.3M−57%$26M−42%$26.2M−38%$29.3M−21%$22M+8%$23.5M−10%$24.7M−6%
−$29.7M+6%−$13.3M−55%−$1.5M−91%$11.7M−$1.7M−94%$21.8M$20.1M$29.7M+153%$33.2M$41.4M+90%$46.3M+131%$35.4M+19%
Interest expense$1.3M$1.3M$1.2M+1743%$1.2M−14%$1.1M−13%$1.1M−17%$1.1M−7%$1.1M−9%$1M−9%$1M−5%$948K−15%$867K−21%
Pre-tax income−$26.4M+5%−$10M−61%$1.5M$14.8M$1.2M$24.3M$22.2M+1399%$32M+116%$35.7M+2943%$43.9M+80%$48.8M+120%$38.7M+21%
$459K−46%$739K+70%$756K$457K+53%−$256K$1M+36%$643K−15%$411K−10%−$175.1M+68300%$9.6M+852%$11.4M+1669%$7M+1606%
Net income−$26.9M+3%−$10.7M−59%$722K$14.3M$1.4M$23.3M$21.5M+2880%$31.6M+120%$210.8M+14651%$34.4M+47%$37.4M+74%$31.7M+1%
−$0.19+6%−$0.07−61%$0.01$0.10$0.01$0.16$0.16+1500%$0.23+130%$1.53+15200%$0.25+56%$0.28+75%$0.23+0%
143.7M+1%144M+1%144.1M+1%145.7M+2%149.7M+4%143.2M−1%137.5M−5%136M−7%137.9M−8%137.6M−4%133.5M−3%135.2M−1%

Gross profit: 27 periods, Q1 FY20 to Q3 FY26: not printed by the filing, worked out from its own lines.

Diluted shares: 4 periods, Q4 FY20 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Aurinia Pharmaceuticals' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
AUPHAurinia Pharmaceuticals$2.2Bn/m28.8×6.7×+21%97.7%
HRMYHarmony Biosciences$2.2B12.3×13.8×2.3×+24%18.9%
PBHPrestige Consumer Healthcare$2.4B13.9×15.3×2.1×−1%15.6%
NRIXNurix Therapeutics$2.8B11.1×11.0×4.0×n/m42.0%
ANIPANI Pharmaceuticals$1.6B15.0×57.5×1.7×+31%11.1%
PAHCPhibro Animal Health$1.6B15.9×21.5×1.0×+17%6.6%
PCRXPacira BioSciences$1.5B104×65.7×1.9×+6%2.0%
ANABAnaptysbio$1.4B10.3×99.3×n/mn/mn/m
OMEROmeros$1.3B11.7×11.7×n/mn/mn/m
OGNOrganon$3.6B18.2×6.0×0.6×−3%3.5%
LQDALiquidia$3.7B30.1×49.4×8.3×n/m30.7%
Peer median$1.9B14.5×18.4×2.0×+11%13.3%

More on Aurinia Pharmaceuticals

Each number over time

Where it ranks

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .